Detailed Information

Cited 11 time in webofscience Cited 10 time in scopus
Metadata Downloads

Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data

Authors
Kim, Hae RimYim, Hyung JoonKang, SeongheeSuh, Sang JunKim, Seung YoungHyun, Jong JinKoo, Ja SeolKim, Ji HoonSeo, Yeon SeokYeon, Jong EunLee, Sang WooByun, Kwan SooUm, Soon Ho
Issue Date
Mar-2015
Publisher
Blackwell Publishing Inc.
Keywords
cirrhosis; entecavir; hepatitis B; telbivudine
Citation
Liver International, v.35, no.3, pp.860 - 869
Indexed
SCIE
SCOPUS
Journal Title
Liver International
Volume
35
Number
3
Start Page
860
End Page
869
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8094
DOI
10.1111/liv.12605
ISSN
1478-3223
Abstract
Background & Aims Entecavir (ETV) is effective in the treatment of chronic hepatitis B virus (HBV) infections, even in patients with underlying cirrhosis. However, there is little information on the effect of telbivudine (TBV) in chronic hepatitis B patients with cirrhosis.This study compared the antiviral efficacy of TBV and ETV in HBV-related cirrhosis. Methods We consecutively enrolled 151 treatment-naïve patients with HBV-related cirrhosis who started antiviral therapy with TBV (n = 61) or ETV (n = 90). Results After 24 months of treatment, per-protocol analysis showed similar virological response rates (HBV DNA <20 IU/ml) in the TBV group (80.6%, 25/31) and in the ETV group (90.2%, 74/82) (P = 0.167). However, intention-to-treat analysis showed lower virological response rates in the TBV group (41.7%, 25/60) than in the ETV group (83.1%, 74/89) (P = 0.001). Mean reduction in HBV DNA levels was greater in the ETV group (−3.72 ± 1.94 vs. −4.87 ± 1.57 respectively, P = 0.001). Serologic and biochemical response rates at month 24 did not differ significantly between the groups. Child-Turcotte-Pugh score was significantly improved after 24 months compared to the pretreatment state without difference between the groups. During 24 months of therapy, 15 patients (27.3%) showed antiviral resistance to TBV while no resistance (0%) was reported in the ETV group (P = 0.001). Conclusions Compared to ETV, TBV therapy shows lower efficacy in viral suppression and higher risk of antiviral resistance despite comparable effect on improvement of hepatic function for the treatment of HBV-related cirrhosis.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Hyun, Jong Jin photo

Hyun, Jong Jin
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE